The Middle EAST Bradykinin Mediated Angioedema Market was valued at USD 0.25 billion in 2024 and is projected to reach USD 0.75 billion by 2034, registering a CAGR of 12.0%. This growth trajectory is underpinned by an increasing awareness of angioedema conditions, advancements in treatment options, and a growing patient population. The rising incidence of hereditary angioedema (HAE) and...